InnoCell was established to uniquely lead the explosive growth of the biotechnology industry in Eastern Europe. Our laboratory and services stand out in the region, built with globally benchmarked innovative technology. Our primary focus is on the production of human stem cell preparations, stem cell-based 3D constructs (spheroids), and human stem cell-based disease models, all manufactured to Good Laboratory Practice (GLP) standards for the pharmaceutical and cosmetic industries. In these sectors, particularly in health-related fields, the creation of organs and tissues from human stem cells has led to significant breakthroughs: the use of human cells in preclinical efficacy and toxicology testing is replacing and surpassing traditional animal models. Thus, our aim is to advance innovation in drug development, the pharmaceutical industry, and the cosmetics industry by producing high-quality (GLP) human cell-based test systems that partially replace and exceed animal experimental models.
OUR SERVICES
Unique technology and expertise in Eastern Europe
Pluripotent stem cells can generate tissues such as bone, cartilage, and cardiac muscle, which can be implanted at specific sites in the body to restore the function of damaged tissues. While this therapeutic field is still in its early stages of development, the use of various tissues derived from human stem cells in preclinical efficacy and toxicology studies is increasingly replacing traditional animal models. The development of appropriate culturing, differentiation, and genetic modification technologies is currently underway. However, the stable, certified, and appropriately licensed (GLP-compliant) production of human stem cell preparations is already a fundamental requirement for regulatory acceptance in preclinical studies. At InnoCell, we have undertaken the task of establishing these highly reliable technologies for preclinical testing and drug development in Eastern Europe.
TECHNOLOGY
Ethical and sustainable development
At InnoCell, we prioritize supporting large-scale advancements in an ethical and sustainable manner. The guidelines from the U.S. Food and Drug Administration (FDA) and the European Medicines Agency (EMA) increasingly advocate for the use of human cell-based test systems in preclinical drug development and toxicology studies to reduce animal testing [EMA/CHMP/CVMP/JEG-3Rs/450091/2012, 15 December 2016]. In the cosmetics industry, preclinical animal testing is already prohibited. Consequently, there is a growing demand for human cell-based test systems manufactured under GLP (Good Laboratory Practice) and GMP (Good Manufacturing Practice) conditions.
PUBLICATIONS
Knowledge. Reliability. Recognition.
At InnoCell, we place a high emphasis on expertise and reliability. Beyond our GLP certification, our assurance lies in our team of internationally recognized experts. Collectively, our team possesses decades of experience in healthcare, the pharmaceutical industry, and stem cell research.
OUR TEAM
Providing High Quality Test Services For Your Health!
Helping To Deliver Answers For Health Questions.
World Class Diagnostics
We have developed some of the world's most advanced testing capabilities to help improve health and lives.
Leader in Drug Development
With the support of our diagnostics capabilities to deliver drug trials that are both reliable and rigorous.
We process more than 3 million patient specimens per week and help medical professionals and patients make important health decisions, by identifying patterns and even individuals who might benefit from enrollment in specific drug trials.
